{'52WeekChange': 'Infinity',
 'SandP52WeekChange': None,
 'address1': '11055 Flintkote Avenue',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 4.49,
 'askSize': 800,
 'averageDailyVolume10Day': 482187,
 'averageVolume': 814064,
 'averageVolume10days': 482187,
 'beta': 1.47731,
 'beta3Year': None,
 'bid': 4.44,
 'bidSize': 800,
 'bookValue': None,
 'category': None,
 'circulatingSupply': None,
 'city': 'San Diego',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 4.69,
 'dayLow': 4.42,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -2.904,
 'enterpriseToRevenue': 189.701,
 'enterpriseValue': 47484948,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '858 952 7571',
 'fiftyDayAverage': 4.0208573,
 'fiftyTwoWeekHigh': 5.75,
 'fiftyTwoWeekLow': 0.83,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 9730659,
 'forwardEps': None,
 'forwardPE': None,
 'fromCurrency': None,
 'fullTimeEmployees': 12,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.00191,
 'heldPercentInstitutions': 0.11395001,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/cardiffoncology.com',
 'longBusinessSummary': 'Cardiff Oncology, Inc., a clinical-stage, oncology '
                        'therapeutic company, develops drugs to treat various '
                        'types of cancer, including leukemia, lymphomas, and '
                        'solid tumors. Its lead drug candidate is onvansertib, '
                        'a Polo-like Kinase 1 selective adenosine triphosphate '
                        'competitive inhibitor that is in Phase Ib/II clinical '
                        'trial in acute myeloid leukemia (AML); has completed '
                        'a Phase I clinical trial in advanced solid tumors; '
                        'and Phase Ib/II clinical trial for metastatic '
                        'Colorectal Cancer in combination with FOLFIRI and '
                        "Avastin. The company's onvansertib is also in Phase "
                        'II clinical trial in combination with Zytiga for '
                        'metastatic castration-resistant prostate cancer; '
                        'Phase I clinical trial with various chemotherapies '
                        'and targeted therapeutics, such as Beleodaq '
                        '(belinostat); Quizartinib (AC220), a development '
                        'stage FLT3 inhibitor; and Velcade (bortezomib) used '
                        'in leukemias, lymphomas, and solid tumor cancers. It '
                        'primarily serves pharmaceutical companies. Cardiff '
                        'Oncology, Inc. has a research collaboration with '
                        'Nektar Therapeutics for the treatment of metastatic '
                        'colorectal cancer. The company was formerly known as '
                        'Trovagene, Inc. and changed its name to Cardiff '
                        'Oncology, Inc. in May 2020. Cardiff Oncology, Inc. '
                        'was founded in 1999 and is headquartered in San '
                        'Diego, California.',
 'longName': 'Cardiff Oncology, Inc.',
 'market': 'us_market',
 'marketCap': 89656768,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_10959548',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -16622190,
 'nextFiscalYearEnd': 1640908800,
 'open': 4.69,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '858 952 7570',
 'previousClose': 4.66,
 'priceHint': 4,
 'priceToBook': None,
 'priceToSalesTrailing12Months': 358.17578,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 4.69,
 'regularMarketDayLow': 4.42,
 'regularMarketOpen': 4.69,
 'regularMarketPreviousClose': 4.66,
 'regularMarketPrice': 4.69,
 'regularMarketVolume': 157204,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 19968100,
 'sharesPercentSharesOut': 0.0273,
 'sharesShort': 545359,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 256923,
 'shortName': 'Cardiff Oncology, Inc.',
 'shortPercentOfFloat': 0.0273,
 'shortRatio': 0.58,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'CRDF',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': None,
 'twoHundredDayAverage': 2.9162858,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '66310195-132e-37e2-aefd-b05ac5a2eb8a',
 'volume': 157204,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.cardiffoncology.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '92121'}